GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Aequus Pharmaceuticals Inc (OTCPK:AQSZF) » Definitions » 3-Year EPS without NRI Growth Rate

Aequus Pharmaceuticals (Aequus Pharmaceuticals) 3-Year EPS without NRI Growth Rate : -26.00% (As of Mar. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Aequus Pharmaceuticals 3-Year EPS without NRI Growth Rate?

Aequus Pharmaceuticals's EPS without NRI for the three months ended in Mar. 2024 was $-0.00.

During the past 3 years, the average EPS without NRI Growth Rate was -26.00% per year. During the past 5 years, the average EPS without NRI Growth Rate was 15.10% per year. During the past 10 years, the average EPS without NRI Growth Rate was 22.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 11 years, the highest 3-Year average EPS without NRI Growth Rate of Aequus Pharmaceuticals was 45.00% per year. The lowest was -26.00% per year. And the median was 26.20% per year.


Competitive Comparison of Aequus Pharmaceuticals's 3-Year EPS without NRI Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Aequus Pharmaceuticals's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aequus Pharmaceuticals's 3-Year EPS without NRI Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Aequus Pharmaceuticals's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Aequus Pharmaceuticals's 3-Year EPS without NRI Growth Rate falls into.



Aequus Pharmaceuticals 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.


Aequus Pharmaceuticals  (OTCPK:AQSZF) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.


Aequus Pharmaceuticals 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Aequus Pharmaceuticals's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Aequus Pharmaceuticals (Aequus Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
200 Granville Street, Suite 2820, Vancouver, BC, CAN, V6C 1S4
Aequus Pharmaceuticals Inc is a Canada-based specialty pharmaceutical company. The firm's operating segments are the Commercial platform and Development pipeline. It generates a majority of its revenue from the Commercial platform segment. The Company earns revenues from the sale of dry eye products and by providing promotional services to sell third-party-owned products, namely Tacrolimus IR and Vistitan.